Psoriasis Clinical Trial

Peds Metabolic Syndrome in Psoriasis

Summary

The objective of this study is to assess whether there is an increased risk of the metabolic syndrome in children with psoriasis compared to children without psoriasis.

View Full Description

Full Description

Adult patients with psoriasis, especially those who are young and with severe disease, have an increased prevalence of myocardial infarction and metabolic syndrome, and increased mortality. Tumor Necrosis Factor (TNF) and other inflammatory cytokines are felt to play an important role not only in the pathogenesis of psoriasis and psoriatic arthritis, but in the pathogenesis of the metabolic syndrome and increased cardiovascular mortality and morbidity.

However, the prevalence of metabolic syndrome and surrogate markers of increased cardiovascular risk, such as lower flow-mediated dilation (FMD) during reactive hyperemia, measured by high-resolution brachial artery ultrasound, lower hyperemia-induced, pulse wave amplitudes as measured by finger plethysmograph peripheral artery tonometry, and elevated blood CRP levels, in children with psoriasis, are unknown.

We will use the definition of metabolic syndrome described by de Ferranti: Participants are defined as having metabolic syndrome if they meet or exceed the criteria for 3 or more of the following 5 variables: 1) triglycerides ≥1.1 mmol/L; 2) HDL cholesterol <1.3 mmol/L; 3) fasting blood glucose ≥6.1 mmol/L; 4) waist circumference (cm) >75th percentile for age and sex; and 5) systolic or diastolic blood pressure (mm Hg) >90th percentile for age, sex, and height.

The following two noninvasive procedures will be used to assess additional cardiovascular risk: flow mediated dilation (FMD) and finger plethysmography peripheral artery tonometry (PAT). These procedures have been used extensively to measure adults for clinical study purposes for many years.

As a control group, we will compare children with psoriasis to age-, race-,and gender-matched children with warts.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

10-17 year old children with either moderate to severe psoriasis or with warts
For psoriasis patients, body surface area covered must be 5% or more or must have had a documented history of 5% or more body surface area involvement
Ability to understand and sign an age-appropriate consent form
Parent or Guardian over 18 years old able to understand and sign consent form

Exclusion Criteria:

Psoriasis or wart patient younger than 10 or 18 years or older
For psoriasis patients, body surface area covered less than 5% or have not had a documented history of 5% or more body surface area involvement
Inability of child or adult parent/guardian to understand or sign consent
Pregnant or lactating females.

Study is for people with:

Psoriasis

Estimated Enrollment:

42

Study ID:

NCT00930592

Recruitment Status:

Completed

Sponsor:

Tufts Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Tufts Medical Center, Department of Dermatology
Boston Massachusetts, 02111, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Estimated Enrollment:

42

Study ID:

NCT00930592

Recruitment Status:

Completed

Sponsor:


Tufts Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider